Cagrilintide, Research Reference

Cagrilintide is a synthetic long-acting amylin analogue developed by Novo Nordisk. It acts on amylin receptors concentrated in the area postrema and hypothalamic nuclei involved in energy regulation, producing satiety signalling and slowing gastric emptying. Unlike GLP-1 receptor agonists such as semaglutide, cagrilintide targets the amylin receptor system, a pharmacologically distinct pathway that converges on overlapping but non-identical appetite-regulating circuits. This distinction forms the mechanistic rationale for the CagriSema combination, which pairs cagrilintide with semaglutide to engage both systems simultaneously.

Quick Reference

Overview

Amylin is a 37-amino acid peptide hormone co-secreted alongside insulin by pancreatic beta cells in response to food intake. It acts peripherally and centrally to reduce meal size, slow gastric emptying, and suppress postprandial glucagon release. Native amylin has a very short plasma half-life, measured in minutes, limiting its therapeutic utility. Pramlintide, an earlier amylin analogue approved for type 1 and type 2 diabetes, requires multiple daily injections because of this limitation.

Cagrilintide achieves an approximately 7-day half-life through fatty acid conjugation, the same albumin-binding strategy used to extend semaglutide’s half-life for once-weekly dosing. This pharmacokinetic modification makes once-weekly subcutaneous administration feasible for cagrilintide, aligning it with the weekly dosing interval of the GLP-1 class and enabling its co-formulation with semaglutide in CagriSema.

Cagrilintide has been studied in:

• Phase 1 and Phase 2 monotherapy trials by Novo Nordisk evaluating doses up to 4.5 mg once weekly, reporting weight loss and tolerability data
• Phase 1b combination trials with semaglutide (Enebo et al., The Lancet, 2021)
• The Phase 3 REDEFINE CagriSema programme (ongoing), which uses 2.4 mg cagrilintide as the amylin component

As of 2026, cagrilintide has not received independent regulatory approval in any jurisdiction. Its clinical development has proceeded primarily in the context of the CagriSema combination rather than as a standalone agent.

Mechanism of Action

Amylin Receptor Agonism

Cagrilintide acts on amylin receptors, which are heterodimeric complexes formed by the calcitonin receptor (CTR) combined with receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3) to produce the AMY1, AMY2, and AMY3 receptor subtypes, respectively. This receptor family is pharmacologically distinct from GLP-1 receptors (which belong to the class B G protein-coupled receptor superfamily but are structurally separate from the calcitonin receptor family).

Amylin receptors are concentrated in the area postrema (a hindbrain circumventricular organ with access to peripheral signals) and in hypothalamic nuclei involved in energy homeostasis, including the arcuate nucleus and paraventricular nucleus. Cagrilintide activates these receptors to produce:

• Satiety signalling through area postrema and hypothalamic pathways, reducing meal size and increasing the interval between meals
• Slowing of gastric emptying, prolonging the sensation of fullness after meals
• Suppression of postprandial glucagon secretion from pancreatic alpha cells
• Modulation of dopaminergic reward pathways associated with food-motivated behaviour

Distinct Mechanism from GLP-1 Agonism

GLP-1 receptors and amylin receptors are expressed in partially overlapping but non-identical neuronal populations. Both systems modulate appetite and gastric emptying, but they do so through distinct receptor-level signalling events and through neurons that, while converging on similar downstream energy-balance outputs, are not the same cells or circuits.

The clinical implication is that combining a GLP-1 receptor agonist (semaglutide) with an amylin receptor agonist (cagrilintide) may engage appetite-suppressing circuitry more completely than either agent alone. Phase 2 data from the CagriSema development programme support this hypothesis: the combination produced approximately 15 percent body weight reduction at 32 weeks, compared with approximately 9 percent with semaglutide 2.4 mg alone in the same trial (Frias et al., The Lancet, 2021).

Fatty Acid Conjugation and Pharmacokinetics

The approximately 7-day half-life of cagrilintide results from fatty acid modification that enables non-covalent binding to albumin in the circulation. Albumin-bound cagrilintide is protected from renal clearance and enzymatic degradation. It dissociates from albumin transiently to engage amylin receptors, then rebinds. This mechanism is structurally analogous to, but distinct from, the albumin-binding approach used for semaglutide, and explains why both compounds can be co-formulated for once-weekly dosing in CagriSema.

Reported Protocols

The following information represents dosing ranges drawn from published clinical trial protocols. This is not a medical recommendation.

Monotherapy Dosing Context

Novo Nordisk Phase 1 and Phase 2 monotherapy trials evaluated cagrilintide using escalating dose protocols reaching up to 4.5 mg once weekly. The trials characterised pharmacokinetics, pharmacodynamics, and weight effects across the dose range, demonstrating that weight loss was dose-dependent and that gastrointestinal side effects were the primary tolerability concern.

Dose escalation was used in these trials to reduce early gastrointestinal events, mirroring the approach taken for GLP-1 receptor agonists. The principle is consistent: slower escalation from a lower starting dose is associated with better tolerability during initiation.

As of 2026, no approved label exists defining a therapeutic monotherapy dose for cagrilintide. Standalone dosing references in research contexts are primarily derived from the published trial literature rather than from approved therapeutic guidance.

CagriSema Combination Context

The most commonly referenced cagrilintide dose in current research literature is 2.4 mg once weekly, reflecting the cagrilintide component dose in the Phase 3 REDEFINE CagriSema programme. In this context, cagrilintide is co-administered with semaglutide 2.4 mg in a single weekly subcutaneous injection, following a dose-escalation schedule over approximately 16 weeks before reaching the 2.4 mg maintenance dose.

• Frequency: Once weekly, same day each week
• Injection sites: Abdomen, thigh, or upper arm; rotate sites between injections
• Target dose (CagriSema context): 2.4 mg cagrilintide per injection

Researchers consulting cagrilintide data outside the CagriSema context should note that standalone dosing is less established and that most reported effects data come from combination rather than monotherapy trial conditions.

Reported Effects

The following effects have been reported in clinical research and are summarised from published trial data and the broader amylin receptor agonism literature. This list reflects the research landscape and does not constitute confirmed outcomes for any specific individual.

Body Weight Reduction

Cagrilintide monotherapy Phase 2 data demonstrated meaningful, dose-dependent weight loss in trial participants with obesity, with effects apparent at doses below the 2.4 mg CagriSema-context reference dose and increasing through the escalation range. The available monotherapy data support that amylin receptor agonism alone produces clinically relevant weight reduction, though the magnitude is less than that reported for GLP-1 monotherapy at comparable development stages.

The most robust efficacy data for cagrilintide are from the combination context. Phase 2 CagriSema data showed approximately 15 percent body weight reduction at 32 weeks (vs. approximately 9 percent for semaglutide 2.4 mg alone). Phase 3 REDEFINE data show approximately 22 to 25 percent mean body weight reduction over 68 weeks with CagriSema. These figures reflect the combined activity of both components and cannot be attributed to cagrilintide alone, but they establish the clinical relevance of amylin receptor agonism as part of the combination mechanism.

Appetite Suppression and Satiety

Research has characterised cagrilintide’s primary mechanism as appetite suppression through area postrema and hypothalamic amylin receptor activation. Reported effects include reductions in meal size, earlier satiety onset, and extended time between meals. These effects are mechanistically complementary to GLP-1 receptor agonist-mediated satiety, operating through different receptor populations in partially overlapping neural circuits.

Gastric Emptying Delay

Cagrilintide slows gastric emptying through amylin receptor-mediated signalling, prolonging postprandial satiety. This effect is mechanistically parallel to, but receptor-pathway-distinct from, the gastric emptying delay produced by semaglutide and other GLP-1 agonists.

Glucagon Suppression

Amylin receptor agonism suppresses postprandial glucagon secretion from pancreatic alpha cells, contributing to improved postprandial glycaemic control. This effect complements the glucose-dependent glucagon suppression and insulin secretion stimulation of the semaglutide component in CagriSema.

Reported Side Effects

Reported side effects in research and clinical trial accounts include the following. This list does not constitute a comprehensive safety profile.

The gastrointestinal side effect profile is the primary tolerability concern with cagrilintide, consistent with amylin receptor agonism as a class and with GLP-1 receptor agonists when cagrilintide is used in the CagriSema combination. The gradual dose-escalation protocols used in clinical trials are designed to reduce the incidence and severity of nausea and vomiting during initiation.

An increased heart rate has been observed in the context of amylin receptor agonism and is considered a class-level effect. Its magnitude and clinical significance in long-term use continue to be characterised in the REDEFINE programme data.

When combined with semaglutide in CagriSema, gastrointestinal side effects may reflect contributions from both components. The CagriSema clinical trial tolerability data indicate that the combined profile is manageable in the majority of trial participants when the titration schedule is followed, though a minority of participants have discontinued due to gastrointestinal events.

The risk of cholelithiasis is consistent with observations for agents that produce rapid weight loss, including GLP-1 receptor agonists as a class.

Storage & Handling

Pre-Use Storage

Cagrilintide in clinical trial and research peptide contexts is handled as a solution for subcutaneous injection. Guidelines consistent with other injectable amylin and GLP-1 class peptides apply:

• Refrigerator (2-8°C): Required storage condition; do not freeze
• Light sensitivity: Store in original packaging or an opaque container to protect from light
• Room temperature: Brief periods below 30°C may be acceptable during transport; specific guidance depends on formulation and context

Reconstitution (Research Peptide Context)

For researchers working with cagrilintide as a lyophilized research peptide rather than a pre-formulated clinical trial product:

• Reconstitute with bacteriostatic water (BAC water), adding diluent slowly along the vial wall; swirl gently, do not shake
• Store reconstituted solution at 2-8°C; use within 4-6 weeks of reconstitution
• Do not freeze a reconstituted solution
• Discard if the solution appears cloudy, discoloured, or contains visible particles
• See the Reconstitution Guide for full step-by-step instructions and volume calculations

Frequently Asked Questions

What is cagrilintide? Cagrilintide is a synthetic long-acting amylin analogue developed by Novo Nordisk. Amylin is a peptide hormone co-secreted with insulin by pancreatic beta cells in response to food intake. Native amylin has a very short plasma half-life; cagrilintide extends this to approximately 7 days through fatty acid conjugation, enabling once-weekly subcutaneous dosing. It acts on amylin receptors (AMY1, AMY2, and AMY3) in the area postrema and hypothalamus, producing satiety and slowing gastric emptying. Cagrilintide has been studied both as a monotherapy and as the amylin component of CagriSema.

Is cagrilintide the same as CagriSema? No. CagriSema is a combination product pairing cagrilintide 2.4 mg with semaglutide 2.4 mg in a single weekly injection. Cagrilintide is one of its two active components. Semaglutide is the other, a GLP-1 receptor agonist. Cagrilintide acts on amylin receptors; semaglutide acts on GLP-1 receptors. These are pharmacologically distinct systems. Cagrilintide has been studied in Phase 1 and Phase 2 monotherapy trials separately, but most of its clinical efficacy data come from the CagriSema combination context.

How does cagrilintide differ from GLP-1 agonists like semaglutide? Cagrilintide and semaglutide act on entirely different receptor systems. Semaglutide is a GLP-1 receptor agonist that reduces appetite through hypothalamic and brainstem GLP-1 receptors, stimulates glucose-dependent insulin secretion, and slows gastric emptying. Cagrilintide acts on amylin receptors (AMY1, AMY2, AMY3), which are heterodimers of the calcitonin receptor with RAMP co-receptor proteins. Both systems converge on satiety and gastric emptying, but through distinct receptor populations in partially overlapping neural circuits. This pharmacological distinction is the basis for combining them in CagriSema.

What is the reported dosing for cagrilintide as a standalone compound? Novo Nordisk Phase 1 and Phase 2 monotherapy trials evaluated doses up to 4.5 mg once weekly using escalating protocols. The 2.4 mg once-weekly dose is the most commonly referenced figure because it is the cagrilintide component dose in the CagriSema Phase 3 REDEFINE programme. Standalone cagrilintide dosing is considerably less established than the CagriSema combination dosing. There is no approved therapeutic label defining a monotherapy dose. Most real-world dosing context comes from the combination programme.

What side effects are reported with cagrilintide? Nausea, vomiting, and decreased appetite are the most commonly reported side effects, particularly during dose escalation, consistent with amylin analogue class effects. Injection site reactions and occasional headache have been reported. An increased heart rate is a class-level effect of amylin receptor agonism. When combined with semaglutide in CagriSema, the gastrointestinal profile reflects contributions from both components and mirrors the GLP-1 class tolerability pattern; gradual dose escalation reduces early gastrointestinal events in most trial participants.

Related Pages

Goals: Fat Loss | Metabolic Health | Appetite & Weight Management

Class: GLP-1 Agonists

Stacks: Retatrutide + Cagrilintide Stack

Also see: Semaglutide (GLP-1 component of CagriSema) | Retatrutide (triple GIP/GLP-1/glucagon agonist) | Orforglipron (oral GLP-1 receptor agonist)

References & Further Reading

• Enebo LB, et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg for obesity (SCALE CAGRISEMA): a randomised, double-blind, controlled, phase 1b trial. The Lancet, 397(10286), 2199-2210. PubMed ->
• Frias JP, et al. (2021). Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, active-controlled, double-blind, phase 2 trial. The Lancet, 397(10286), 2212-2224. PubMed ->
• Novo Nordisk. REDEFINE Phase 3 clinical trial programme. ClinicalTrials.gov identifier NCT04986943 and related registrations. ClinicalTrials.gov ->
• Larsen PJ, et al. (2010). Physiology of amylin and its pharmacological application. Background reference for amylin receptor biology underlying cagrilintide development.
• Drucker DJ. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 27(4), 740-756. PubMed ->
• Bhatt DL, et al. (2023). Amylin receptor agonism in obesity: mechanistic rationale and clinical development context for combination therapy approaches.